NOF Polysorbate 80 is in compliance with the Chinese Pharmacopoeia

10/29/2019
by NOF EUROPE GmbH

We are pleased to inform you that we submitted a drug master file to CDE (Center for Drug Evaluation, National Medical Products Administration) for our Polysorbate 80 (HX2)TM .

Polysorbate 80 (HX2)TM, which is our ultrapure polysorbate 80, is now in compliance with the United States Pharmacopeia [USP], the European Pharmacopoeia [EP], the Japanese Pharmacopoeia [JP], and the Chinese Pharmacopoeia [ChP for injection].

You can use Polysorbate 80 (HX2)TM for development of various pharmaceutical products for the Chinese market.

Comments

No posts found